These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 20685900)

  • 41. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal.
    Singh SP; Singh V; Kar N
    Int J Neuropsychopharmacol; 2012 Apr; 15(3):417-28. PubMed ID: 21859514
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Agomelatine in treating generalized anxiety disorder.
    Demyttenaere K
    Expert Opin Investig Drugs; 2014 Jun; 23(6):857-64. PubMed ID: 24766542
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Agomelatine treatment of major depressive disorder.
    Dolder CR; Nelson M; Snider M
    Ann Pharmacother; 2008 Dec; 42(12):1822-31. PubMed ID: 19033480
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
    San L; Arranz B
    Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients.
    Quera-Salva MA; Hajak G; Philip P; Montplaisir J; Keufer-Le Gall S; Laredo J; Guilleminault C
    Int Clin Psychopharmacol; 2011 Sep; 26(5):252-62. PubMed ID: 21829106
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries.
    Arango C; Buitelaar JK; Fegert JM; Olivier V; Pénélaud PF; Marx U; Chimits D; Falissard B;
    Lancet Psychiatry; 2022 Feb; 9(2):113-124. PubMed ID: 34919834
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.
    Stahl SM; Fava M; Trivedi MH; Caputo A; Shah A; Post A
    J Clin Psychiatry; 2010 May; 71(5):616-26. PubMed ID: 20361916
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder.
    Kennedy SH; Heun R; Avedisova A; Ahokas A; Olivier V; Picarel-Blanchot F; de Bodinat C
    J Affect Disord; 2018 Oct; 238():122-128. PubMed ID: 29879606
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder.
    Shu L; Sulaiman AH; Huang YS; Fones Soon Leng C; Crutel VS; Kim YS
    Asian J Psychiatr; 2014 Apr; 8():26-32. PubMed ID: 24655622
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders].
    Lôo H; Daléry J; Macher JP; Payen A
    Encephale; 2002; 28(4):356-62. PubMed ID: 12232545
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.
    Bourin M; Prica C
    Curr Pharm Des; 2009; 15(14):1675-82. PubMed ID: 19442180
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The importance of early symptom relief in antidepressant treatment: focus on agomelatine.
    Lam RW
    J Psychopharmacol; 2010 Aug; 24(2 Suppl):27-30. PubMed ID: 20663806
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Agomelatine treatment of major depressive disorder in Parkinson's disease: a case series.
    De Berardis D; Fornaro M; Serroni N; Olivieri L; Marini S; Moschetta FS; Srinivasan V; Assetta M; Valchera A; Salone A; Martinotti G; Onofrj M; Di Giannantonio M
    J Neuropsychiatry Clin Neurosci; 2013; 25(4):343-5. PubMed ID: 24247862
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder.
    Kennedy SH; Avedisova A; Giménez-Montesinos N; Belaïdi C; de Bodinat C;
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):553-63. PubMed ID: 24530273
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Agomelatine in the treatment of major depressive disorder: assessment of the efficacy and tolerability].
    Filippova NV; Barylnik YB; Shuldyakov AA; Antonova AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(5):154-161. PubMed ID: 31317905
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT
    Tchekalarova J; Kortenska L; Ivanova N; Atanasova M; Marinov P
    Psychopharmacology (Berl); 2020 Feb; 237(2):503-518. PubMed ID: 31720718
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Agomelatine: An Astounding Sui-generis Antidepressant?
    Naveed M; Li LD; Sheng G; Du ZW; Zhou YP; Nan S; Zhu MY; Zhang J; Zhou QG
    Curr Mol Pharmacol; 2022; 15(7):943-961. PubMed ID: 34886787
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Circadian rhythms, melatonin and depression.
    Quera Salva MA; Hartley S; Barbot F; Alvarez JC; Lofaso F; Guilleminault C
    Curr Pharm Des; 2011; 17(15):1459-70. PubMed ID: 21476953
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder.
    Kennedy SH; Grouin JM; Cadour S; Robert V; Picarel-Blanchot F
    Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29327372
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders].
    Lôo H; Daléry J; Macher JP; Payen A
    Encephale; 2003; 29(2):165-71. PubMed ID: 14567168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.